Univariate and multivariable analyses for progression free survival. by Huriye Senay Kiziltan (22298378)

Subjects:

Kaplan Meier curves of OS and PFS according to different pre-RT different D-dimer values. by Huriye Senay Kiziltan (22298378)

Subjects:

Univariate and multivariable analyses for OS. by Huriye Senay Kiziltan (22298378)

Subjects:

Characteristics of LC patients. by Huriye Senay Kiziltan (22298378)

Subjects:

Decision curve analysis according to t D-dimer values in patients with OS ≥ 1 year and those with OS < 1 year. by Huriye Senay Kiziltan (22298378)

Subjects:

Kaplan Meier curves of OS and PFS according to d-dimer values comparing OS rates between patients with D-dimer levels ≤ 0.3 µg/mL and those with levels > 0.3 µg/mL. by Huriye Senay Kiziltan (22298378)

Subjects:

ROC curve according to their D-dimer values in patients with OS ≥ 1 year and those with OS < 1 year. p < 0.001 (95% CI: 6-24). by Huriye Senay Kiziltan (22298378)

Subjects:

Flowchart of this study. by Huriye Senay Kiziltan (22298378)

Subjects:

RT characteristics and D-dimer, OS and PFS of patients. by Huriye Senay Kiziltan (22298378)

Subjects:

Compressed sensing decoded pooled testing significantly decreases the number of tests required to identify infected samples. by Kody A. Waldstein (14002708)

Trends in the burden of stroke attributed to smoking. by Jaber S. Alqahtani (8822396)

Pharmacological inhibition of EGFR decreases early fungal burden and reduces the inflammatory response. by Marc Swidergall (185453)

Duration of blood pressure decrease. by Ai Wei (120010)

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects: